DOCSLIB.ORG

Drug Update for 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Update for 2020 NEW DRUG UPDATE SERIES 6 JAN 2020 NEW DRUG UPDATE SERIES 4, NOV 2019 1. KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Centre and Hospital Limited) Coimbatore, Tamilnadu SERIES 6 JAN 2020 DEPARTMENT OF PHARMACOLOGY- NEW DRUG UPDATE Contents Strive for Novelty FDA – NEW DRUG APPROVALS 1. Golodirsen 2. Enfortumab vedotin-ejfv 3. Brilliant Blue G Ophthalmic Solution 4. Lumateperone tosylate 5. Lemborexant 6. Fam-trastuzumab deruxtecan-nxki 7. Ubrogepant D E P A R T M E N T O F P H A R M A C O L O G Y , K M C H I H S R Page 1 NEW DRUG UPDATE SERIES 6 JAN 2020 Date of Adverse Drug Dosage S.No Drug Name Mechanism of Action Indications FDA Reactions Formulation Approval 1. Golodirsen An antisense Duchenne muscular Headache, pyrexia, Intravenous 12/12/2019 oligonucleotide. Binds to dystrophy with fall, abdominal pain, Injection exon 53 of dystrophin mutation of the DMD nasopharyngitis, pre-mRNA exclusion gene that is amenable cough, vomiting, and of exon 53 to exon 53 skipping nausea 2. Enfortumab Nectin-4-directed IgG1 Locally advanced or Fatigue, peripheral Intravenous 18/12/2019 vedotin-ejfv antibody and metastatic refractory neuropathy, loss of Injection microtubule inhibitor urothelial cancer appetite, rash, conjugate alopecia, nausea, dry eye, diarrhea 3. Brilliant Blue Selectively stain the Dye used in eye Due to surgical Intraocular 20/12/2019 G Ophthalmic internal limiting surgery to selectively procedure - retinal Injection Solution membrane stain the internal - break, tear, limiting membrane hemorrhage, detachment & cataract 4. Lumateperone 5-HT2A antagonism and An atypical Somnolence / Capsule 20/12/2019 tosylate central D2 postsynaptic antipsychotic to treat sedation and dry antagonism schizophrenia mouth (No EPS & Metabolic syndrome) 5. Lemborexant Orexin receptor Insomnia with sleep Somnolence Tablet 20/12/2019 antagonist onset and/or sleep maintenance difficulty 6. Fam- HER2-directed antibody Unresectable or Nausea, alopecia, Intravenous 20/12/2019 trastuzumab and topoisomerase metastatic refractory constipation or Injection deruxtecan- inhibitor conjugate HER2-positive breast diarrhea, loss of nxki cancer appetite, anemia, pancytopenia and cough 7. Ubrogepant Calcitonin gene-related Acute treatment of Nausea and Tablet 23/12/2019 peptide receptor migraine with or somnolence antagonist without aura in adults Kindly Mail Your Suggestions To: [email protected] Access this series COMPILED & EDITED by through the KMCH website Department of Pharmacology www.kmchihsr.edu.in KMCHIHSR, Coimbatore, 641014 D E P A R T M E N T O F P H A R M A C O L O G Y , K M C H I H S R Page 2 NEW DRUG UPDATE SERIES 7 FEB 2020 NEW DRUG UPDATE SERIES 4, NOV 2019 1. KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Centre and Hospital Limited) Coimbatore, Tamilnadu SERIES 7 FEB 2020 DEPARTMENT OF PHARMACOLOGY- NEW DRUG UPDATE Date of Mechanism Adverse Drug Dosage S.No Drug Name Indications FDA of Action Reactions Formulation Approval 1. Avapritinib Tyrosine Unresectable or Edema, nausea, Tablet 09/01/2020 kinase metastatic fatigue/asthenia, inhibition Gastrointestinal cognitive impairment, stromal tumor vomiting, decreased harboring a platelet- appetite, diarrhea, hair derived growth color changes, increased factor receptor lacrimation, abdominal alpha exon 18 pain, constipation, rash mutation and dizziness. 2. Teprotumumab-trbw Insulin-like Thyroid eye disease Muscle spasm, nausea, Intravenous 21/01/2020 growth alopecia, diarrhea, Injection – factor-1 fatigue, headache Lyophilized receptor hyperglycemia, hearing powder in a inhibition impairment, dry skin, single vial for dysgeusia reconstitution 3. Tazemetostat Histone Locally advanced Pain, fatigue, nausea, Tablet 23/01/2020 methyl Epithelioid sarcoma decreased appetite, transferase in adults and vomiting, and constipation inhibition pediatric patients aged 16 years and older Kindly Mail Your Suggestions To: [email protected] COMPILED & EDITED by Access this series Department of Pharmacology through the KMCH website KMCHIHSR, Coimbatore, 641014 www.kmchihsr.edu.in Strive For Novelty D E P A R T M E N T O F P H A R M A C O L O G Y , K M C H I H S R Page 1 New drug update Series 8 March 2020 NEW DRUG UPDATE SERIES 4, NOV 2019 1. KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Center and Hospital Limited) Coimbatore, Tamilnadu SERIES 8 MARCH 2020 DEPARTMENT OF PHARMACOLOGY- NEW DRUG UPDATE Creating the Future Inside this series New Drug Approvals by FDA 1. Eptinezumab-jjmr 2. Bempedoic acid 3. Amisulpride 4. Bempedoic acid and Ezetimibe New drugs Available drugs with new 5. Rimegepant formulation D E P A R T M E N T O F P H A R M A C O L O G Y , K M C H I H S R Page 1 New drug update Series 8 March 2020 1. Eptinezumab-jjmr 2. Bempedoic acid 3. Amisulpride • Date of Approval: February 21, • Date of Approval: February 21, • Date of Approval: February 26, 2020 2020 2020 • Mechanism of action: • Mechanism of action: First-in- • Mechanism of action: Monoclonal antibody - CGRP class, Adenosine triphosphate- Dopamine antagonist antagonist citrate lyase inhibitor • Indication: Post-Operative • Indication: Preventive • Indication: Heterozygous Nausea & Vomiting treatment of Migraine in adults Familial Hypercholesterolemia • Dosage Formulation: Injection • Dosage Formulation: Injection • Dosage Formulation: Tablet for Intravenous Infusion for Intravenous use 4. Bempedoic acid and 5. Rimegepant Ezetimibe • Date of Approval: February 27, •Date of Approval: February 26, 2020 2020 • Mechanism of action: •Mechanism of action: Adenosine Calcitonin gene-related peptide triphosphate-citrate lyase inhibitor receptor antagonist and a cholesterol absorption inhibitor combination • Indication: Acute treatment of Migraine •Indication: Heterozygous Familial Hypercholesterolemia • Dosage Formulation: Orally •Dosage Formulation: Tablet Disintegrating Tablet Kindly Mail Your Suggestions To: COMPILED & EDITED by [email protected] Department of Pharmacology KMCHIHSR, Coimbatore, 641014 Access this series through KMCHIHSR website www.kmchihsr.edu.in D E P A R T M E N T O F P H A R M A C O L O G Y , K M C H I H S R Page 2 KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Center and Hospital Limited) Coimbatore, Tamil Nadu Every Day, A New Discovery Department Of Pharmacology New Drug Update (New Drugs and Available Drugs with New Formulation) Series - 9 April 2020 In this series 1.Isatuximab-irfc Date of Approval: March 2, 2020 New drugs approved by FDA Mechanism of action: CD38-directed cytolytic antibody Indication: Multiple Myeloma in combination with Pomalidomide and Dexamethasone 1. Isatuximab-irfc Dosage Formulation: IV Infusion 2. Bimatoprost Implant 2.Bimatoprost Implant Date of Approval: March 3, 2020 3. Osilodrostat Mechanism of action: PG-F2α analogue, reduces IOP Indication: Open Angle Glaucoma 4. Ozanimod Dosage Formulation: Intra-cameral, Biodegradable Sustained-Release Implant 3.Osilodrostat (Received Orphan Drug Designation) Date of Approval: March 6, 2020 Mechanism of action: Cortisol synthesis inhibitor COMPILED & EDITED by Indication: Adults with Cushing's Syndrome who cannot undergo pituitary gland surgery or have undergone Department of Pharmacology surgery KMCHIHSR, Coimbatore. Dosage Formulation: Tablet **************************************************** Kindly Mail Your Suggestions To: 4.Ozanimod [email protected] Date of Approval: March 25, 2020 Access this series through website: Mechanism of action: Sphingosine 1-phosphate receptor www.kmchihsr.edu.in modulator Indication: Relapsing Multiple Sclerosis 641014 Dosage Formulation: Capsule Department of Pharmacology, KMCHIHSR 1| P a g e KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Center and Hospital Limited) Coimbatore,Tamilnadu Series 10 Department of Pharmacology May 2020 New drug update Inside the series a ❖ Sacituzumab-govitecan-hziy A passion for better medicine ❖ Coagulation factor VIIa recombinant-jncw ❖ Selumetinib Compiled & Edited by ❖ Tucatinib Department of Pharmacology, KMCHIHSR, ❖ Opicapone Coimbatore, 641014. ❖ Pemigatinib Kindly Mail Your Suggestions To: ❖ Ephedrine sulphate (premixed hodpharmacology@ kmchihsr.edu.in formulation) ❖ Mitomycin(pyelocalyceal solution) Access this series through the KMCH website www.kmchihsr.edu.in Department of Pharmacology, KMCHIHSR PAGE 1 Sacituzumab-govitecan-hziy Coagulation factor VIIa recombinant-jncw Approval date – April 22, 2020 Approval date – April 1, 2020 Mechanism of Trop-2-directed antibody and Mechanism of Coagulation factor VIIa action topoisomerase inhibitor action concentrate conjugate Indication Previously-treated metastatic Indication Patients aged 12 years and older Triple-Negative Breast Cancer with Hemophilia A or B with (mTNBC) inhibitors Dosage IV infusion (as Lyophilized Dosage IV injection (as Lyophilized formulation powder for reconstitution) formulation powder for reconstitution) Selumetinib Tucatinib Approval date – April 10, 2020 Approval date – April 17, 2020 Mechanism of A mitogen activated protein Mechanism of action A kinase inhibitor kinases1&2(MEK1/2)inhibitor action Indication Paediatric patients aged 2 years & Indication Patients with advanced metastatic older with symptomatic inoperable HER2 +ve Breast carcinoma along Neurofibromatosis 1(NF1) with trastuzumab &capecitabine Dosage Dosage Tablet formulation Capsule formulation Opicapone Pemigatinib Approval date – April 24, 2020 Approval date –
Load more

Recommended publications
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • January 2021 Update
    PUBLISHED JULY 08, 2021 OCTOBER/DECEMBER 2020; JANUARY 2021 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the update to the Highmark Drug Formularies and pharmaceutical management procedures for January 2021. The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in October, December, and January by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Healthcare Reform Essential Formulary C. Changes to the Highmark Core Formulary D. Changes to the Highmark National Select Formulary E. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left. Highmark Blue Cross Blue Shield Delaware is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides secure, web-based portal between providers and health insurance companies. IMPORTANT DRUG SAFETY UPDATES 03/31/2021 – Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • 62. Deutscher Kongress Für Endokrinologie
    62. Deutscher Kongress für Endokrinologie dge2019.de TAGUNGS- FÜHRER 20.–22. März 2019 © Conny Blaack M.A., kunst & mediendesign, 37130 Gleichen/Bremke GÖTTINGEN Kongresspräsidentin: HAUPTTHEMEN Prof. Dr. Heide Siggelkow Knochen als hormonelles Organ Wissenschaftliche Kongresssekretärin: Vitamin D, das endokrine und Dr. Katja Gollisch metabolische System Kongressorganisation: Individualisierte Osteoporosetherapie EndoScience Endokrinologie Service GmbH Update Andrologie nach Berthold Endokrine Onkologie Mittwoch, 20.03.2019 Programmübersicht Raum Lichtenberg Raum Gauss Raum Heisenberg Raum Gebrüder Grimm Raum Göttinger Sieben 09:00 – 10:30 Vorstandssitzung 09:00 – 12:00 S. 18 Sektionstreffen YARE / MuSkITYRS 10:30 – 11:30 Pressekonferenz S. 18 S. 18 11:30 – 12:30 Eröffung der Industrieausstellung S. 19 12:30 – 13:00 Kongresseröffnung S. 19 13:00 – 13:45 Aktuelles zur Mikrobiom-Hor- mon-Achse: Prof. Dr. Bar- bara Obermayer- Pietsch, Graz, Österreich S. 19 13:45 – 14:15 Lunch 13:45 – 14:45 Akromegalieregister 14:00 – 15:00 Neugründung 14:15 – 15:15 14:00 – 16:00 S. 19 der AG Labor Satelliten Symposium 1: 14:15 – 15:45 S1: Vom Tiermodell zum UCB Pharma GmbH S. 20 Satelliten Symposium 2: Menschen – Aktuelles S. 22 Merck Serono GmbH zur Reproduktions- endokrinologie S. 22 15:45 – 16:15 Kaffeepause S. 20 16:00 – 17:30 16:15 – 17:15 16:00 – 17:30 S2: Hypophysen- Sektionstreffen MTE 1 16:15 – 17:45 15:00 – 19:15 erkrankungen Reproduktions- MTE 2 S3 Hauptthema: Endokrinologie in der Schwangerschaft biologie und -medizin Cortisol und Knochen: für die Praxis S. 24 Freunde oder Feinde? update 2019 S. 23 S. 23/24 (kostenpflichtig) separate Anmeldung S.
    [Show full text]
  • Pipeline Report November 2020
    Pipeline Report November 2020 Pipeline Report November 2020 © 2020 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs: Recent Specialty Drug Approvals1 1 > On COVID-19, the FDA granted full approval to Veklury (remdesivir) for the treatment of COVID-19. Veklury is approved for use in hospitalized adults and pediatric patients (≥ 12 years of age and weighing ≥ 40 Recent Non-Specialty Drug Approvals 6 kg), and represents the very first therapy to garner full FDA approval for COVID-19. Other therapies will follow, gaining market access through EUA (LLY’s Bamlanivimab and Olumiant, and <likely> Regeneron’s Upcoming Specialty Products 7 REGN-COV2). With the US crossing the 11 million total coronavirus infection mark, demand for these agents will be high while supply of the antibody treatment will be especially tight. The vaccine race accelerates as there are now two m-RNA based candidates both showing greater than 94% Upcoming Non-Specialty Products 15 efficacy in study populations. Both vaccines require 2 doses. Neither has FDA approval, and EUA reviews are pending. Supplies will be limited for months to come. Pfizer has stated it could produce 50 million doses by the end of 2020, and Moderna has promised up to 20 million doses in the same time frame. During 2021 Pfizer Biosimilars 18 forecasts 1.3 billion doses while Moderna states between 500 million and 1 billion.
    [Show full text]
  • Health Plan Insights
    Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
    [Show full text]
  • Human Growth Hormone
    Clinical Policy: Human Growth Hormone (Somapacitan, Somatropin) Reference Number: CP.PCH.39 Effective Date: 03.01.21 Last Review Date: 02.21 Coding Implications Line of Business: Commercial, HIM Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The following human growth hormone (hGH) formulations require prior authorization: • hGH analogs: somapacitan-beco (Sogroya®) • Recombinant hGH (rhGH) formulations: somatropin (Genotropin®, Humatrope®, Norditropin®, Nutropin AQ®, Omnitrope®, Saizen®, Serostim®, Zomacton®, Zorbtive®) Drugs Children Adults GHD PWS TS NS SHOX CKD SGA ISS GHD HIV SBS Sogroya X Genotropin GF GF GF GF GF X SS/ SS/ SS/ SS/ Humatrope SS/GF X GF GF GF GF Norditropin GF GF SS SS SS SS X NutropinAQ GF GF GF GF X Omnitrope GF GF GF GF GF X Saizen GF X Serostim X Zomacton GF SS SS SS SS X Zorbtive X Abbreviations: CKD: chronic kidney disease, GF: growth failure, GHD: growth hormone deficiency, HIV: human immunodeficiency virus, ISS: idiopathic short stature, NS: Noonan syndrome, PWS: Prader-Willi syndrome, SBS: short bowel syndrome, SGA: small for gestational age, SHOX: short stature homeobox-containing gene, SS: short stature, TS: Turner syndrome FDA Approved Indication(s) hGH Analogs: Sogroya is indicated for: • Replacement of endogenous GH in adults with GHD rhGH Formulations: Genotropin is indicated for treatment of: • Children with GF due to GHD, PWS, SGA, TS, and ISS. • Adults with either childhood-onset (CO) or adult-onset (AO) GHD. Humatrope is indicated for treatment of: • Children with SS or GF associated with GHD, TS, ISS, SHOX deficiency, and failure to catch up in height after SGA birth.
    [Show full text]
  • Management of Hypopituitarism
    Journal of Clinical Medicine Review Management of Hypopituitarism Krystallenia I. Alexandraki 1 and Ashley B. Grossman 2,3,* 1 Endocrine Unit, 1st Department of Propaedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece; [email protected] 2 Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford OX3 7LE, UK 3 Centre for Endocrinology, Barts and the London School of Medicine, London EC1M 6BQ, UK * Correspondence: [email protected] Received: 18 November 2019; Accepted: 2 December 2019; Published: 5 December 2019 Abstract: Hypopituitarism includes all clinical conditions that result in partial or complete failure of the anterior and posterior lobe of the pituitary gland’s ability to secrete hormones. The aim of management is usually to replace the target-hormone of hypothalamo-pituitary-endocrine gland axis with the exceptions of secondary hypogonadism when fertility is required, and growth hormone deficiency (GHD), and to safely minimise both symptoms and clinical signs. Adrenocorticotropic hormone deficiency replacement is best performed with the immediate-release oral glucocorticoid hydrocortisone (HC) in 2–3 divided doses. However, novel once-daily modified-release HC targets a more physiological exposure of glucocorticoids. GHD is treated currently with daily subcutaneous GH, but current research is focusing on the development of once-weekly administration of recombinant GH. Hypogonadism is targeted with testosterone replacement in men and on estrogen replacement therapy in women; when fertility is wanted, replacement targets secondary or tertiary levels of hormonal settings. Thyroid-stimulating hormone replacement therapy follows the rules of primary thyroid gland failure with L-thyroxine replacement.
    [Show full text]
  • Growth Hormones Is Recommended in Those Who Meet the Following Criteria
    Policy: 95015 Initial Effective Date: 06/22/1995 HCPCS J2170, J2940, J2941 and Q0515 Code(s): Annual Review Date: 06/17/2021 SUBJECT: Growth Stimulating Drugs Last Revised Date: 07/15/2021 - Genotropin(somatropin injection) - Humatrope (somatropin injection) - Increlex (mecasermin) - Norditropin® (somatropin injection) - Nutropin AQ (somatropin injection) - Omnitrope® (somatropin injection) - Saizen® (somatropin injection) - Serostim (somatropin injection) - Zomacton™ (somatropin injection) - Zorbtive (somatropin injection) - Sogroya(somapacitan injection) Prior approval is required for some or all procedure codes listed in this Corporate Drug Policy. Definition: Exogenous growth hormone (recombinant human, rhGH) is a polypeptide hormone with metabolic effects similar to endogenous human growth hormone (GH). Produced in the pituitary gland, endogenous growth hormone activates production of insulin-like growth factor-1 (IGF-1) and other peptides that: modulate lipid, carbohydrate and protein metabolism; and stimulate development of bone, cartilage, skeletal muscle and gonadal tissue, leading to longitudinal growth. Inadequate secretion or impairment of growth hormone activity during childhood and adolescence may result in short stature, growth hormone deficiency with growth failure and other medical conditions. Exogenous growth hormone products approved by the U.S. Food and Drug Administration include somatropin (Humatrope®, Nutropin®, Serostim®, Saizen®, Norditropin®, Genotropin®, Zorbtive®, Omnitrope®, ZomactonTM). These products are
    [Show full text]
  • Drug Utilization R Eview B Oard
    OHCA Webinar Wednesday, March 10, 2021 Review Board 4:00pm Please register for the webinar at: https://zoom.us/s/97305655255 After registering, you will receive a confirmation email containing information about joining the webinar. Drug Utilization The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Michyla Adams, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – March 10, 2021 DATE: February 22, 2021 NOTE: In response to COVID-19, the March 2021 DUR Board meeting will be held via OHCA webinar at 4:00pm. Please register for the meeting using the following website address: https://zoom.us/s/97305655255 After registering, you will receive a confirmation email containing information about joining the webinar. Enclosed are the following items related to the March meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Quarterly Review of the Medication Therapy Management (MTM) Program – Appendix B Update on Medication Coverage Authorization Unit/Spring 2021 Pipeline Update – Appendix C Action Item – Vote to Prior Authorize Anjeso® (Meloxicam Injection) and Licart™ (Diclofenac Epolamine Topical System) – Appendix D Action Item – Vote to Prior Authorize Oxlumo™ (Lumasiran) – Appendix E Action Item – Vote to Prior Authorize Fintepla® (Fenfluramine) – Appendix F Action Item – Vote to Prior Authorize Teriparatide – Appendix G
    [Show full text]
  • Lists of Medicinal Products for Rare Diseases in Europe*
    March 2021 Lists of medicinal products for rare diseases in Europe* the www.orpha.net www.orphadata.org General Table of contents PART 1: List of orphan medicinal products in Europe with European orphan designation and European marketing authorization 3 Table of contents 3 Methodology 3 Classification by tradename 5 Annex 1: Orphan medicinal products withdrawn from the European Community Register of orphan medicinal products 22 Annex 2: Orphan medicinal products withdrawn from use in the European Union 31 Classification by date of MA in descending order 33 Classification by ATC category 34 Classification by MA holder 35 PART 2 : 37 List of medicinal products intended for rare diseases in Europe with European marketing authorization without an orphan designation in Europe 37 Table of contents 37 Methodology 37 Classification by tradename 38 Classification by date of MA in descending order 104 Classification by ATC category 106 Classification by MA holder 108 For any questions or comments, please contact us: [email protected] Orphanet Report Series - Lists of medicinal products for rare diseases in Europe. March 2021 http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf 2 PART 1: List of orphan medicinal products in Europe with European orphan designation and European marketing authorization* Table of contents List of orphan medicinal products in Europe with European orphan designation and European marketing authorisation* 3 Methodology 3 Classification by tradename 5 Annex 1: Orphan medicinal products removed or withdrawn from the European Community Register of orphan medicinal products 22 Annex 2: Orphan medicinal products withdrawn from use in the European Union 31 Classification by date of MA in descending order 33 Classification by ATC category 34 Classification by MA holder 35 Methodology This part of the document provides the list of all orphan with the list of medicinal products that have been granted a medicinal products that have received a European Marketing marketing authorization (http://ec.europa.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]